Integra LifeSciences Holdings Corporation $IART Holdings Lowered by Leeward Investments LLC MA

Leeward Investments LLC MA trimmed its stake in shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART) by 3.6% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 374,809 shares of the life sciences company’s stock after selling 13,939 shares during the quarter. Leeward Investments LLC MA’s holdings in Integra LifeSciences were worth $4,599,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in IART. Caitong International Asset Management Co. Ltd raised its position in shares of Integra LifeSciences by 205.9% during the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 3,132 shares of the life sciences company’s stock worth $38,000 after buying an additional 2,108 shares in the last quarter. AlphaQuest LLC bought a new stake in shares of Integra LifeSciences during the 2nd quarter worth about $73,000. CWM LLC raised its position in shares of Integra LifeSciences by 32.6% during the 2nd quarter. CWM LLC now owns 8,834 shares of the life sciences company’s stock worth $108,000 after buying an additional 2,170 shares in the last quarter. MassMutual Private Wealth & Trust FSB raised its position in shares of Integra LifeSciences by 6,017.6% during the 2nd quarter. MassMutual Private Wealth & Trust FSB now owns 10,094 shares of the life sciences company’s stock worth $124,000 after buying an additional 9,929 shares in the last quarter. Finally, Compass Financial Group INC SD bought a new stake in shares of Integra LifeSciences during the 2nd quarter worth about $172,000. 84.78% of the stock is currently owned by institutional investors.

Integra LifeSciences Stock Up 1.5%

NASDAQ IART opened at $16.12 on Monday. The company’s 50 day simple moving average is $14.72 and its 200 day simple moving average is $13.92. The company has a market capitalization of $1.26 billion, a P/E ratio of -2.47 and a beta of 1.21. The company has a debt-to-equity ratio of 1.18, a current ratio of 1.23 and a quick ratio of 0.73. Integra LifeSciences Holdings Corporation has a 12 month low of $11.06 and a 12 month high of $27.13.

Integra LifeSciences (NASDAQ:IART) last released its quarterly earnings results on Thursday, July 31st. The life sciences company reported $0.45 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.43 by $0.02. Integra LifeSciences had a negative net margin of 30.87% and a positive return on equity of 12.15%. The business had revenue of $415.61 million for the quarter, compared to analyst estimates of $395.06 million. During the same quarter in the previous year, the business earned $0.63 earnings per share. The firm’s revenue was down .6% compared to the same quarter last year. Integra LifeSciences has set its FY 2025 guidance at 2.190-2.290 EPS. Q3 2025 guidance at 0.400-0.450 EPS. Equities research analysts expect that Integra LifeSciences Holdings Corporation will post 2.45 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

IART has been the topic of a number of recent analyst reports. Citigroup restated a “sell” rating and set a $12.00 price target (up from $10.00) on shares of Integra LifeSciences in a research report on Tuesday, October 7th. Truist Financial set a $15.00 target price on shares of Integra LifeSciences and gave the stock a “hold” rating in a report on Wednesday, October 15th. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Integra LifeSciences in a report on Saturday. Two analysts have rated the stock with a Buy rating, two have issued a Hold rating and four have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Reduce” and an average price target of $16.17.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.